Psirenity Health Announces an Exclusive Offer Through the Oakville Chamber of Commerce’s “Chamber Perks” App
Oakville, Ontario--(Newsfile Corp. - June 28, 2024) - Psirenity Health, a member of the Oakville Chamber of Commerce, is pleased...
Day: June 28, 2024
THIRA Health Welcomes Dr. Al Tsai, MD, as New Medical Director
Thira Health Expands Clinical Expertise With Appointment of Dr. Al TsaiBELLEVUE, WA / ACCESSWIRE / June 28, 2024 / THIRA...
NLS Pharmaceutics Announces Registered Direct Offering
ZURICH, SWITZERLAND / ACCESSWIRE / June 28, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage...
FSD Pharma, Inc. Wins Final Judgment to Confirm Arbitration Award of $3,059,998 Plus Interest Entered Against Dr. Raza Bokhari, Currently Serving as Chairman and CEO of Medicus Pharma Ltd.
TORONTO, ON / ACCESSWIRE / June 28, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), a biopharmaceutical company dedicated to...
Biotricity Launches HeartSecure: Immediate, At-Home Cardiac Screening Now Available
Democratizing cardiac health with convenient, rapid, and reliable results REDWOOD CITY, CA / ACCESSWIRE / June 28, 2024 / Biotricity...
EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Marketing Authorization Of Moderna’s RSV Vaccine, mRESVIA(R)
CAMBRIDGE, MA / ACCESSWIRE / June 28, 2024 / Moderna, Inc. (Nasdaq:MRNA) today announced that the European Medicines Agency's (EMA)...
Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership
JUPITER, Fla., June 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI), announced today that they have entered...
Intelligent Bio Solutions Completes In-Clinic Portion of Pharmacokinetic (PK) Study Part of 510(k) Pathway for Approval & Commences Review of Results
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical...
Safety Shot President Jordan Schur Invests $1 Million in the Company Through his Family Fund, Core 4 Capital Corp.
This Private Placement Investment Comes in Addition to a $5 Million Investment from Core 4 Capital Corp Which Closed in April...
Ardelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare Disciplines
WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to...
Eyenovia Announces Pricing of $5M Registered Direct Offering
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company,...
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency
- European Commission decision anticipated in the second half of 2024 - BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Rhythm...
Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome
REDWOOD CITY, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing...
Inovalon and MEDITECH Collaborate to Transform and Optimize Revenue Cycle
SaaS Healthcare Leader Joins MEDITECH Alliance to Optimize Patient Intake and Payment ProcessesBOWIE, Md., June 28, 2024 (GLOBE NEWSWIRE) --...
Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment
Vancouver, Canada, June 28, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a...
CHMP adopts positive opinion for BALVERSA® (erdafitinib) for the treatment of adult patients with unresectable or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations
Pending approval, erdafitinib would become the first therapy targeting FGFR3 alterations in patients with metastatic urothelial carcinoma, one of Europe’s...
Roche’s Vabysmo gets CHMP recommendation for third indication retinal vein occlusion (RVO)
Positive recommendation is based on two Phase III studies. In addition to robust retinal drying with Vabysmo, these data show...
Orchard Therapeutics Celebrates Global Progress toward Advancing Newborn Screening for MLD on International Neonatal Screening Day
A nomination to add MLD to the U.S. Recommended Uniform Screening Panel has been submitted by a multi-disciplinary expert working...
Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Recommendation based on data from the Phase 1 and pivotal Phase 2 trials demonstrating robust and durable response rates in...
23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel
SOUTH SAN FRANCISCO, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading preventive health and...